301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1818844852040761344 |
|---|---|
| author | Ralf Gutzmer Caroline Robert Thomas Eigentler Qian Zhu Helen Gogas Grant McArthur Paolo Ascierto Daniil Stroyakovskiy Svetlana Protsenko Rodrigo Pereira Lev Demidov Georgy Moiseevich Manikhas Haocheng Li Edward McKenna Virginia McNally |
| author_facet | Ralf Gutzmer Caroline Robert Thomas Eigentler Qian Zhu Helen Gogas Grant McArthur Paolo Ascierto Daniil Stroyakovskiy Svetlana Protsenko Rodrigo Pereira Lev Demidov Georgy Moiseevich Manikhas Haocheng Li Edward McKenna Virginia McNally |
| author_sort | Ralf Gutzmer |
| collection | DOAJ |
| first_indexed | 2024-12-19T05:20:20Z |
| format | Article |
| id | doaj.art-e85259d827c149f2a0ae7f4ca214a744 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-12-19T05:20:20Z |
| publishDate | 2020-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-e85259d827c149f2a0ae7f4ca214a7442022-12-21T20:34:32ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0301301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 studyRalf Gutzmer0Caroline Robert1Thomas Eigentler2Qian Zhu3Helen Gogas4Grant McArthur5Paolo Ascierto6Daniil Stroyakovskiy7Svetlana Protsenko8Rodrigo Pereira9Lev Demidov10Georgy Moiseevich Manikhas11Haocheng Li12Edward McKenna13Virginia McNally1417 Department of Dermatology and Allergy, Skin Cancer Center Hannover, Hannover Medical School, Hannover, Germany 4 Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France Aff1 0000 0001 0196 8249grid.411544.1Center for Dermatooncology, Department of DermatologyUniversity Hospital Tuebingen Liebermeisterstr. 25 72076 Tuebingen Germany Department of Obstetrics and Gynecology, International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, ChinaAff1 0000 0001 2155 0800grid.5216.0First Department of Medicine, Laiko General HospitalNational and Kapodistrian University of Athens School of Medicine 11527 Athens Greece Aff2 grid.1055.10000000403978434Peter MacCallum Cancer Centre East Melbourne Australia 6Istituto Nazionale Tumori IRCCS ‘Fondazione G. Pascale’, Naples, Italy4Moscow City Oncology Hospital #62, Istra, Russian Federation6N. N. Petrov Nat’l Medical Research Ctr of Oncology, St. Petersburg, Russian Federation7Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil10N. N. Blokhin Russian Cancer Research, Moscow, Russian Federation11St. Petersburg Oncology Hospital, St. Petersburg, Russian Federation12F. Hoffmann–La Roche Ltd, Mississauga, Canada13Genentech, Inc., South San Francisco, CA, USA14Roche Products Ltd., Welwyn Garden City, UK |
| spellingShingle | Ralf Gutzmer Caroline Robert Thomas Eigentler Qian Zhu Helen Gogas Grant McArthur Paolo Ascierto Daniil Stroyakovskiy Svetlana Protsenko Rodrigo Pereira Lev Demidov Georgy Moiseevich Manikhas Haocheng Li Edward McKenna Virginia McNally 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study Journal for ImmunoTherapy of Cancer |
| title | 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study |
| title_full | 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study |
| title_fullStr | 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study |
| title_full_unstemmed | 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study |
| title_short | 301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study |
| title_sort | 301 association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 imspire150 study |
| work_keys_str_mv | AT ralfgutzmer 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT carolinerobert 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT thomaseigentler 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT qianzhu 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT helengogas 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT grantmcarthur 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT paoloascierto 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT daniilstroyakovskiy 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT svetlanaprotsenko 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT rodrigopereira 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT levdemidov 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT georgymoiseevichmanikhas 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT haochengli 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT edwardmckenna 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study AT virginiamcnally 301associationofresponsewithsurvivaloutcomeswithatezolizumabincombinationwithvemurafenibandcobimetinibinthephase3imspire150study |